Argenx
ARGX
#439
Rank
A$82.19 B
Marketcap
A$1,315
Share price
-0.85%
Change (1 day)
57.15%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): A$23.66

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$22.80. In 2025 the company made an earnings per share (EPS) of A$30.40 an increase over its 2024 EPS that were of A$20.07.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$23.66-22.15%
2025A$30.4051.44%
2024A$20.07-369.77%
2023A-$7.44-60.46%
2022A-$18.8263.33%
2021A-$11.52-40.37%
2020A-$19.32183.47%
2019A-$6.82123.09%
2018A-$3.0654.93%
2017A-$1.9714.07%
2016A-$1.7313.05%
2015A-$1.53-36.34%
2014A-$2.40209.04%
2013A-$0.78-33.99%
2012A-$1.18185.59%
2011A-$0.41